| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Procaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Proxymetacaine adverse reaction |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| codeinphosphat 10 mg/10 ml + kaolin 3 g/10 ml mikstur |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Kaolin and morphine mixture BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 sachet effervescent powder for conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 60 mg and paracetamol 1 g effervescent powder for oral suspension sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing kaolin and morphine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing magnesium sulfate in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction caused by nitrous oxide (disorder) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to cyclopropane |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to surface and infiltration anaesthetic |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to tetracaine |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction caused by peripheral nerve and plexus blocking anesthetic (disorder) |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to spinal anesthetic |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to hallucinogen |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to cannabis |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to lysergide |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to mescaline |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to psilocin |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to psilocybin |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Drug reaction to anticonvulsant |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to other anticonvulsant |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to anticonvulsants NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to antiparkinsonism drugs NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to anticonvulsant and antiparkinsonism drugs NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to other gaseous anesthetics |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to gaseous anesthetic NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to intravenous anesthetic NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to other general anesthetics |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to local anesthetics NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to other local anesthetics |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to hallucinogen NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to other psychotropic agent |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to psychotropic agent NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Drug reaction - CNS drug NOS |
Causative agent |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| CNS-lægemiddel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing N-methyl-D-aspartate receptor antagonist product receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride + naloxone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| buprenorphinhydrochlorid 2 mg + naloxonhydrochlorid 0,5 mg sublingval resoriblet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| buprenorphinhydrochlorid 8 mg + naloxonhydrochlorid 2 mg sublingval resoriblet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 30 mg/30 ml injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| galantamin 4 mg/ml sukkerfri oral opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| ropinirol startpakning med 250 µg+500 µg+1000 µg tabletter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| ropinirol opfølgningspakning med 0,5 mg+1 mg+2 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 10 mg/1 ml i fyldt injektionssprøjte |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| buprenorphin 35 µg/time depotplaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| buprenorphin 52,2 µg/time depotplaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| buprenorphin 70 µg/time depotplaster |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxycodonhydrochlorid 5 mg tablet med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| lægemidler anvendt ved neuropatiske smerter |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxycodonhydrochlorid 10 mg/ml injektionsvæske, opløsning, ampul a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| oxycodonhydrochlorid 10 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid + fentanyl |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid + fentanyl 0,1%/2µg/mL injektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Rivastigmine (as rivastigmine tartrate) 2 mg/mL oral solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Aspirin+papaveretum 500mg/10mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Papaveretum 10mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Papaveretum 20mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| lithium OG/ELLER lithiumforbindelse |
Is a |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Caffeine |
Is a |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Theobromine |
Is a |
True |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing levomethadyl (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| levomethadylacetathydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydrocodonpolistirex + chlorpheniraminpolistirex |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydrocodonpolistirex 10 mg + chlorphenireminpolistirex 8 mg 5 ml oral suspension med modificeret udløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| methadonhydrochlorid 25 mg/ml injektionsvæske, opløsning, ampul a 2 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| methadonhydrochlorid 50 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing aspirin and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing guaifenesin and hydrocodone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| pethidinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydrocodone and phenylephrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing codeine and phenylephrine and promethazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing codeine and guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat 10 mg/ml liposom depotinjektion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorphenamine and hydrocodone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorphenamine and codeine and phenylephrine and potassium iodide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing codeine and guaifenesin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Chlorphenamine- and hydrocodone- and pseudoephedrine-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| hydrocodonbitartrat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorphenamine and guaifenesin and hydrocodone and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| morphinsulfat + glucose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| nalbuphinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| acetylsalicylsyre + oxycodonhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydrocodone and phenylpropanolamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| propoxyphenhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| propoxyphennapsylat |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorphenamine and codeine and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| ropinirolhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing codeine and paracetamol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and codeine 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Aspirin 325 mg and codeine 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| Product containing dezocine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| dezocin 5 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| dezocin 10 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
| dezocin 15 mg/ml injektionsvæske, opløsning, ampul a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Central nervous system agent (substance) |
Inferred relationship |
Some |
|
FHIR